全文获取类型
收费全文 | 1805篇 |
免费 | 126篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 80篇 |
妇产科学 | 28篇 |
基础医学 | 313篇 |
口腔科学 | 54篇 |
临床医学 | 146篇 |
内科学 | 421篇 |
皮肤病学 | 39篇 |
神经病学 | 305篇 |
特种医学 | 50篇 |
外科学 | 136篇 |
综合类 | 3篇 |
预防医学 | 112篇 |
眼科学 | 20篇 |
药学 | 98篇 |
中国医学 | 11篇 |
肿瘤学 | 119篇 |
出版年
2024年 | 6篇 |
2023年 | 21篇 |
2022年 | 53篇 |
2021年 | 76篇 |
2020年 | 44篇 |
2019年 | 58篇 |
2018年 | 60篇 |
2017年 | 68篇 |
2016年 | 67篇 |
2015年 | 79篇 |
2014年 | 89篇 |
2013年 | 98篇 |
2012年 | 157篇 |
2011年 | 156篇 |
2010年 | 86篇 |
2009年 | 68篇 |
2008年 | 111篇 |
2007年 | 98篇 |
2006年 | 115篇 |
2005年 | 79篇 |
2004年 | 72篇 |
2003年 | 65篇 |
2002年 | 65篇 |
2001年 | 8篇 |
2000年 | 7篇 |
1999年 | 17篇 |
1998年 | 15篇 |
1997年 | 14篇 |
1996年 | 13篇 |
1995年 | 10篇 |
1994年 | 9篇 |
1993年 | 6篇 |
1992年 | 6篇 |
1991年 | 4篇 |
1990年 | 5篇 |
1989年 | 2篇 |
1988年 | 4篇 |
1986年 | 2篇 |
1985年 | 2篇 |
1984年 | 4篇 |
1983年 | 3篇 |
1982年 | 5篇 |
1981年 | 3篇 |
1979年 | 2篇 |
1978年 | 3篇 |
1972年 | 1篇 |
1971年 | 2篇 |
1969年 | 2篇 |
1966年 | 1篇 |
1965年 | 1篇 |
排序方式: 共有1945条查询结果,搜索用时 17 毫秒
101.
102.
Sergio Daga Jie Ding Constantinos Deltas Judy Savige Beata S. Lipska-Zitkiewicz Julia Hoefele Frances Flinter Daniel P. Gale Marina Aksenova Hirofumi Kai Laura Perin Moumita Barua Roser Torra Jeff H. Miner Laura Massella Danica Galei Ljubanovi Rachel Lennon Andr B. Weinstock Bertrand Knebelmann Agne Cerkauskaite Susie Gear Oliver Gross A. Neil Turner Margherita Baldassarri Anna Maria Pinto Alessandra Renieri 《European journal of human genetics : EJHG》2022,30(5):507
103.
Maria Francesca Sfondrini Maurizio Pascadopoli Simone Gallo Federico Ricaldone Davide Dirk Kramp Margherita Valla Paola Gandini Andrea Scribante 《Materials》2022,15(2)
Bonding failure is a clinical issue frequently encountered in orthodontic practice. The aim of this study was to evaluate enamel pretreatment both in vitro and clinically using agents with different RDA values before brackets’ bonding, to assess if RDA can affect the Shear Bond Strength (SBS), Adhesive Remnant Index (ARI) and clinical failure rate of orthodontic brackets. For the in vitro study, 220 bovine teeth were pretreated with agents with different RDA values. Subsequently, brackets were bonded. For the clinical study, 20 patients underwent bonding of 20 brackets each with a split-mouth design. Low and high RDA toothpastes were used for enamel pretreatment. SBS, ARI and failures were recorded. Higher SBS values were found for teeth pretreated with lower RDA agents; conversely, lower SBS values were found for teeth pretreated with higher RDA agents (p < 0.05). For high ARI values, RDA increased too (p > 0.05). In the clinical study, a significantly lower failure rate was reported for teeth pretreated with low RDA toothpaste (2.5% in low RDA group, 7.0% in high RDA group; p < 0.05). No significant differences were assessed comparing the two dental arches and anterior and posterior sites. Enamel pretreatment with low RDA toothpastes could increase brackets’ survival rate. Further in vitro and clinical studies would be welcomed to confirm these findings. 相似文献
104.
Margherita Prosperi Elisa Santocchi Letizia Guiducci Jacopo Frinzi Maria Aurora Morales Raffaella Tancredi Filippo Muratori Sara Calderoni 《Nutrients》2022,14(3)
The alteration of the microbiota–gut–brain axis has been recently recognized as a critical modulator of neuropsychiatric health and a possible factor in the etiopathogenesis of autism spectrum disorders (ASD). This systematic review offers practitioners an overview of the potential therapeutic options to modify dysbiosis, GI symptoms, and ASD severity by modulating the microbiota–gut–brain axis in ASD, taking into consideration limits and benefits from current findings. Comprehensive searches of PubMed, Scopus, the Web of Science Core Collection, and EMBASE were performed from 2000 to 2021, crossing terms referred to ASD and treatments acting on the microbiota–gut–brain axis. A total of 1769 publications were identified, of which 19 articles met the inclusion criteria. Data were extracted independently by two reviewers using a preconstructed form. Despite the encouraging findings, considering the variability of the treatments, the samples size, the duration of treatment, and the tools used to evaluate the outcome of the examined trials, these results are still partial. They do not allow to establish a conclusive beneficial effect of probiotics and other interventions on the symptoms of ASD. In particular, the optimal species, subspecies, and dosages have yet to be identified. Considering the heterogeneity of ASD, double-blind, randomized, controlled trials and treatment tailored to ASD characteristics and host-microbiota are recommended. 相似文献
105.
Barbara Frigo Perry Bartelt Bernardino Chiaia Igor Chiambretti Margherita Maggioni 《国际灾害风险科学学报(英文版)》2021,12(1):40-55
On 18 January 2017 a catastrophic avalanche destroyed the Rigopiano Gran Sasso Resort & Wellness(Rigopiano Hotel) in the Gran Sasso National Park in Italy,with ... 相似文献
106.
Muscle disorders are characterized by differential involvement of various muscle groups. Among these, weakness predominantly affecting finger flexors is an uncommon pattern, most frequently found in sporadic inclusion-body myositis. This finding is particularly significant when the full range of histopathological findings of inclusion-body myositis is not found on muscle biopsy. Prominent finger flexor weakness, however, is also observed in other myopathies. It occurs commonly in myotonic dystrophy types 1 and 2. In addition, individual reports and small case series have documented finger flexor weakness in sarcoid and amyloid myopathy, and in inherited myopathies caused by ACTA1, CRYAB, DMD, DYSF, FLNC, GAA, GNE, HNRNPDL, LAMA2, MYH7, and VCP mutations. Therefore, the finding of finger flexor weakness requires consideration of clinical, myopathological, genetic, electrodiagnostic, and sometimes muscle imaging findings to establish a diagnosis. 相似文献
107.
Gastaldi Matteo Scaranzin Silvia Jarius Sven Wildeman Brigitte Zardini Elisabetta Mallucci Giulia Rigoni Eleonora Vegezzi Elisa Foiadelli Thomas Savasta Salvatore Banfi Paola Versino Maurizio Benedetti Luana Novi Giovanni Mancardi Margherita Maria Giacomini Thea Annovazzi Pietro Baroncini Damiano Ferraro Diana Lampasona Vito Reindl Markus Waters Patrick Franciotta Diego 《Journal of neurology》2020,267(12):3555-3564
Journal of Neurology - The detection of antibodies to myelin oligodendrocyte glycoprotein (MOG) is fundamental for the identification of MOG antibody-associated disorders (MOGAD), and the... 相似文献
108.
Erika Borlenghi Chiara Cattaneo Elisa Cerqui Silvana Archetti Diego Bertoli Daniela Bellotti Doriana Gramegna Giulia Soverini Margherita Oberti Francesca Schieppati Chiara Pagani Angela Passi Margherita Sciumé Mirko Farina Cecilia Carbone Claudia Crippa Daniela Dalceggio Alessandra Tucci Giuseppe Rossi 《Hematological oncology》2020,38(5):754-762
Consolidation treatment in acute myeloid leukemia (AML) patients achieving complete remission (CR) is warranted. High-dose cytarabine (HDAC) is considered first choice in favorable risk and an option in intermediate-risk AML. However, its optimal dose and schedule, as well as the benefit of additional chemotherapy agents remain controversial. Herein, we report on the long-term outcome of consecutive unselected AML patients treated with repeated courses of HDAC, with the addition of idarubicin, followed by autologous peripheral blood stem cell (PBSC) support, in order to limit toxicity, according to Northern Italy Leukemia Group (NILG) AML-01/00 study (EUDRACT number 00400673). Among 338 patients consecutively diagnosed from 2001 to 2017 at our center, 148 with high-risk AML (adverse cytogenetic, isolated FLT3-internal tandem duplication mutation, refractory to first induction) were addressed to allogeneic stem cell transplant. All other cases, 186 patients (55%), median age 53 (range 19–75), were considered standard-risk and received the NILG AML-01/00 program. After achieving CR, patients were mobilized with cytarabine 8 g/sqm to collect autologous CD34+-PBSC and received three consolidation cycles with HDAC (20 g/sqm) plus idarubicin (20 mg/sqm) per cycle, followed by reinfusion of limited doses of CD34+ PBSC (1-2x106/kg). The program was completed by 160 (86%) patients. Toxicity was acceptable. Neutrophils recovered a median of 10 days. Treatment-related mortality was 3/160 (1.8%). After a median follow-up of 66.4 months, overall survival (OS) and relapse-free survival (RFS) at 5-years were 61.4% and 52.4%, respectively. Twenty-eight selected patients aged >65 had similar outcomes. According to European leukemia net-2010 classification, the OS and RFS at 5-years were 76.4% and 65% in favorable risk, without differences between molecular subgroups, 52.3% and 47.2% in Intermediate-I, 45.2% and 36.5% in Intermediate-II risk patients, respectively. In conclusion, consolidation including repeated courses of high dose cytarabine and idarubicin, with limited PBSC support, proved feasible and very effective in nonhigh risk patients. The incorporation of novel agents in its backbone may be tested to further improve patient's prognosis. 相似文献
109.
Coppola A Coppola L Luongo C Arciello A Cacciapuoti F Lama D Luongo M Ruggiero L Pastore A Gombos G 《The International journal of angiology》2007,16(1):7-11
Ozonized autohemotransfusion has been used as a complementary therapy in patients with peripheral arterial disease (PAD). To determine whether ozone therapy could acutely modify artery vasodilatory capacity, a flow-mediated dilation test was performed at the brachial artery level before and after an ozonized autohemotransfusion in 16 patients with PAD, mean (± SD) age 55±1.8 years, and 14 healthy volunteers matched for age, sex and body mass index. Before ozonized autohemotransfusion, the mean baseline diameter of the brachial artery was higher in PAD patients than in healthy subjects (4.6±0.54 mm versus 3.6±0.54 mm, P<0.001) while mean flow-mediated brachial artery dilation and percentage of increase in flow were significantly lower in PAD patients than in controls (6.3±6.1% versus 11.8±2.4%, P<0.02; 433±61% versus 580±46%, P<0.02, respectively). No significant changes were observed after ozonized autohemotransfusion, indicating that ozonized autohemotransfusion does not modify endothelium-dependent ischemia-induced vascular reactivity. 相似文献
110.
Crispino P Pica R Angelucci E Consolazio A Rivera M Cassieri C Paoluzi P 《International journal of colorectal disease》2007,22(5):553-558
Several forms of primary and secondary hematological malignancies were rarely observed during the clinical course of inflammatory
bowel diseases (IBD). Patients needing a prolonged treatment with immunosuppressants, such as azathioprine or methotrexate,
with familiarity and genetic predisposition seem to be at a higher risk of leukemia. On the other hand, asthenia, thickness,
and fever may be the symptoms of the onset of each kind of hematological malignancy. The finding of anemia, alteration of
leukocyte count and large undetermined cells may suggest increased probability of abnormal proliferation of a single white
blood cell line. In this report, the occurrence of hematological malignancies is described in five patients affected by IBD
(three with ulcerative colitis and two with Crohn’s disease) attending our Gastroenterology Unit. 相似文献